Spots Global Cancer Trial Database for A Study of People With CD30 Positive Lymphoma in China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of People With CD30 Positive Lymphoma in China
Official Title: A Multi-centre, Non-interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients With CD30 Positive Lymphoma in China (REALM)
Study ID: NCT05506774
Conditions
Interventions
Study Description
Brief Summary: The main aim is to see how adult participants with newly diagnosed or relapsed/refractory CD30+ lymphoma responded to any previous treatment in China. The study sponsor will not be involved in how participants are treated, the study only consists of collecting demographic and clinical records information from the hospital clinical systems. Based on the diagnosis of the disease, participants will be assigned to one of the following groups and their information will be analyzed within that group respectively: * Group A: Participants diagnosed with classical Hodgkin lymphoma (cHL). * Group B: participants diagnosed with non-Hodgkin lymphoma (NHL), including systemic anaplastic large-cell lymphoma \[sALCL\], peripheral T-cell lymphoma-not otherwise specified \[PTCL-NOS\], angioimmunoblastic T-cell lymphoma \[AITL\], extranodal NK/T-cell lymphoma \[ENKTCL\], mycosis fungoides \[MF\], primary cutaneous anaplastic large cell lymphoma \[pcALCL\], diffuse large B-cell lymphoma \[DLBCL\], primary mediastinal B-cell lymphoma \[PMBCL\]).
Detailed Description: This is an observational, non-interventional, retrospective study in participants with newly diagnosed or relapsed/refractory CD30+ lymphoma to describe the treatment pathways, outcomes, and resource use among adult participants. The study will enroll approximately 2800 participants. The data will be collected from participants' medical records between January 1, 2018 and March 31, 2021 and recorded in the in case report forms (CRFs). Participants will be assigned to the following two observational cohorts based on pathological diagnosis: * Cohort A: Participants with cHL * Cohort B: Participants with NHL This multi-center trial will be conducted in China. All participants will be observed for at least 6 months or until death, loss to follow-up, or end of the study, whichever occurs first.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Peking University Third Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Union Hospital AffiliatedProf to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Jiangsu Province Hospital/the Firstaffiliated Hospital Withnanjing Medical University, NanJing, Jiangsu, China
The Firstaffiliated Hospital Ofsoochow University, SuZhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Shandong, Jinan, China
The First Affiliated Hospital of China Medical University, ShenYang, Liaoning, China
Shanghai Tongji Hospital, Shanghai, Shanghai, China
Contact Details
Name: Study Director
Affiliation: Takeda
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
